Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT Guided Reduced-dose Radiotherapy for NPC
NCT04813705Phase 2Recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Local-regional recurrence free survival at 5 years. Started Jan 2022; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04813705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813705.